Cefepime in 2026: The Shortage Continues

If you've been prescribed Cefepime and heard it's on backorder, you're dealing with one of the longest-running drug shortages in the United States. Cefepime — a powerful IV antibiotic critical for treating life-threatening infections — has been in intermittent shortage since 2022, and as of early 2026, the situation has not fully resolved.

This article gives you an honest, up-to-date picture of where things stand and what you can do about it.

Is Cefepime Still in Shortage?

Yes. As of March 2026, Cefepime injection remains on the ASHP (American Society of Health-System Pharmacists) drug shortage list. B. Braun, one of the major manufacturers, continues to report manufacturing delays. Other manufacturers including Baxter, Apotex, and Hospira (Pfizer) have experienced intermittent supply disruptions as well.

The FDA is aware of the shortage and has been working with manufacturers to increase production. However, sterile injectable drugs like Cefepime require specialized manufacturing facilities, and ramping up production is a slow process.

Why Is Cefepime Hard to Find?

Several factors contribute to the ongoing shortage:

• Manufacturing delays: Sterile injectable production requires cleanroom environments and strict quality controls. Equipment maintenance, contamination events, or regulatory inspections can halt production for extended periods.
• Limited manufacturers: Only 4-5 companies produce generic Cefepime for the U.S. market. When one goes offline, the others struggle to absorb the extra demand.
• Rising demand: Antibiotic-resistant infections are increasing, driving higher use of broad-spectrum antibiotics like Cefepime in hospitals.
• Raw material supply chains: Key ingredients for Cefepime are manufactured overseas, adding supply chain fragility.

For a deeper look at the causes, read our article on why Cefepime is so hard to find.

What Does Cefepime Cost in 2026?

Because Cefepime is a generic injectable antibiotic, its cost varies significantly depending on the setting:

• Hospital/inpatient: The cost is typically bundled into your hospital bill and covered by insurance. Patients rarely see a separate line item for the drug itself.
• Outpatient IV therapy: If you receive Cefepime through a home infusion service or outpatient infusion center, the cash price can range from $90 to $400+ for a typical course, depending on the dose and duration.
• With a discount card: Services like SingleCare report coupon prices around $93 for 9 x 2 g vials, significantly less than the average retail price of approximately $363.

For more savings strategies, visit our guide to saving money on Cefepime.

Are There New Options for Patients?

A few developments may help patients in 2026:

New Combination Product: Exblifep

Exblifep (Cefepime/Enmetazobactam) is a newer FDA-approved combination that pairs Cefepime with a beta-lactamase inhibitor. It's designed to treat complicated UTIs and other infections caused by resistant bacteria. While it's not a direct replacement for standard Cefepime, its availability may reduce some demand pressure on the standard Cefepime supply.

Alternative Antibiotics

When Cefepime is unavailable, doctors commonly substitute Ceftazidime, Piperacillin/Tazobactam (Zosyn), or Meropenem. Each has a different spectrum of activity and may be appropriate depending on your specific infection. See our full guide to Cefepime alternatives.

FDA Shortage Mitigation Efforts

The FDA has been actively working with manufacturers to address the shortage, including expediting inspections, facilitating temporary imports of approved foreign versions, and encouraging new manufacturers to enter the sterile injectable market.

How to Find Cefepime in Stock

Even during a shortage, Cefepime is not completely unavailable — it's just harder to find. Here's what you can do:

1. Use Medfinder: Search for Cefepime availability at medfinder.com to see which facilities near you have stock.
2. Check specialty pharmacies: Infusion pharmacies and home health agencies may have access to distributors that retail pharmacies don't use.
3. Ask about different formulations: If the 2 g vials are out of stock, the 1 g or 500 mg vials might be available.
4. Contact your hospital pharmacy: Hospital pharmacists have access to group purchasing organizations and shortage management protocols.

For more strategies, read our article on how to find Cefepime in stock near you.

What Should You Ask Your Doctor?

If you're affected by the Cefepime shortage, here are questions to bring to your next appointment:

• Is there an equivalent antibiotic that would work for my infection?
• Can my treatment plan be adjusted to use a different vial size that might be more available?
• Should we consider an extended infusion protocol to conserve supply?
• Is my kidney function being monitored to ensure safe dosing? (This is especially important — Cefepime can cause neurotoxicity in patients with reduced kidney function.)

Final Thoughts

The Cefepime shortage is a real problem with no quick fix. But patients are not powerless. By staying informed, using tools like Medfinder, communicating openly with your healthcare team, and knowing your alternatives, you can navigate this shortage and still get effective treatment.

We'll continue updating this article as the situation evolves. Bookmark this page and check back for the latest information.